<DOC>
	<DOCNO>NCT02569554</DOCNO>
	<brief_summary>The current study conduct healthy adult subject evaluate effect proton pump inhibitor food pharmacokinetics PF-06463922 , evaluate bioavailability oral solution relative tablet formulation PF-06463922 .</brief_summary>
	<brief_title>PPI And Food Effect Study For PF-06463922 In Healthy Volunteers</brief_title>
	<detailed_description>PF-06463922 selective , ATP competitive small molecule tyrosine kinase inhibitor ( TKI ) Anaplastic Lymphoma Kinase ( ALK ) positive ( ALK+ ) ROS oncogene 1 ( ROS1 ) positive ( ROS1+ ) receptor tyrosine kinase ( RTK ) also potently inhibit ALK kinase domain mutation responsible resistance crizotinib . PF-06463922 develop novel anticancer agent treatment patient advance ALK+ NSCLC ROS1+ NSCLC . The current study Phase 1 , randomize , open label , 4 period , 4 treatment , 4 sequence , crossover study conduct healthy adult subject . Each subject receive four single oral dos 100 mg PF-06463922 tablet alone , tablet food , tablet rabeprazole , oral solution overnight fast least 10 day washout period PF-06463922 dose . Twenty four ( 24 ) subject enrol obtain least 20 evaluable subject complete treatment . Subjects withdraw replace unless total number complete subject fall 20 .</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Healthy female subject nonchildbearing potential and/or male subject Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document . Subject must willing avoid direct sunlight exposure high intensity ultraviolet light exposure Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular Any condition possibly affect drug absorption A positive urine drug screen . Use tobacco nicotine containing product within 90 day screen positive urine cotinine test history regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male within 6 month Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>PF-06463922</keyword>
	<keyword>rabeprazole</keyword>
	<keyword>proton pump inhibitor ( PPI )</keyword>
	<keyword>pharmacokinetics ( PK )</keyword>
	<keyword>food effect</keyword>
</DOC>